Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature.
carbapenemase
case series
cefiderocol
drug-resistant gram-negatives
review
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
11
02
2020
accepted:
18
05
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
Cefiderocol is a new siderophore cephalosporin with activity against carbapenem-resistant gram-negative bacteria. Data on its clinical efficacy are limited to complicated urinary tract infections. We present a series of 3 patients successfully treated with cefiderocol for complicated health care-associated infections and review published case reports.
Identifiants
pubmed: 32548207
doi: 10.1093/ofid/ofaa185
pii: ofaa185
pmc: PMC7284008
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa185Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4384-6
pubmed: 27139465
Clin Infect Dis. 2019 May 17;68(11):1932-1934
pubmed: 30418554
Antibiotics (Basel). 2019 Mar 14;8(1):
pubmed: 30875778
Antimicrob Agents Chemother. 2020 Mar 24;64(4):
pubmed: 31871075
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S544-S551
pubmed: 31724049
Sci Rep. 2019 Oct 29;9(1):15290
pubmed: 31664064
J Antimicrob Chemother. 2019 Nov 1;74(11):3399-3401
pubmed: 31369095
Antimicrob Agents Chemother. 2015 Nov 16;60(2):729-34
pubmed: 26574013
Antimicrob Agents Chemother. 2020 Mar 24;64(4):
pubmed: 31527031
Pharmacotherapy. 2019 Nov;39(11):1113-1118
pubmed: 31550054
Lancet Infect Dis. 2018 Dec;18(12):1319-1328
pubmed: 30509675
J Antimicrob Chemother. 2016 Mar;71(3):670-7
pubmed: 26645269